6-73482209-G-A
Variant summary
Our verdict is Uncertain significance. The variant received 5 ACMG points: 5P and 0B. PM1PM5PP5
The NM_012123.4(MTO1):c.1430G>A(p.Arg477His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000148 in 1,614,060 control chromosomes in the GnomAD database, with no homozygous occurrence. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R477C) has been classified as Likely pathogenic.
Frequency
Consequence
NM_012123.4 missense
Scores
Clinical Significance
Conservation
Publications
- mitochondrial diseaseInheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiencyInheritance: AR, Unknown Classification: DEFINITIVE, STRONG, MODERATE, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Ambry Genetics, G2P
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 5 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000270 AC: 41AN: 152052Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.000167 AC: 42AN: 251480 AF XY: 0.000177 show subpopulations
GnomAD4 exome AF: 0.000135 AC: 198AN: 1461890Hom.: 0 Cov.: 31 AF XY: 0.000154 AC XY: 112AN XY: 727248 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000269 AC: 41AN: 152170Hom.: 0 Cov.: 32 AF XY: 0.000255 AC XY: 19AN XY: 74406 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency Pathogenic:4
This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 477 of the MTO1 protein (p.Arg477His). This variant is present in population databases (rs201544686, gnomAD 0.08%). This missense change has been observed in individuals with combined oxidative phosphorylation deficiency (PMID: 23929671, 29331171, 29440775). ClinVar contains an entry for this variant (Variation ID: 89037). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on MTO1 protein function. Experimental studies have shown that this missense change affects MTO1 function (PMID: 23929671). For these reasons, this variant has been classified as Pathogenic. -
- -
- -
This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PS1,PM2,PM3,PS3,PP3. -
not provided Pathogenic:3
- -
MTO1: PM2, PM3, PM5 -
- -
Inborn genetic diseases Uncertain:1
The c.1550G>A (p.R517H) alteration is located in exon 9 (coding exon 9) of the MTO1 gene. This alteration results from a G to A substitution at nucleotide position 1550, causing the arginine (R) at amino acid position 517 to be replaced by a histidine (H). Based on data from gnomAD, the A allele has an overall frequency of 0.02% (52/282870) total alleles studied. The highest observed frequency was 0.07% (18/25122) of European (Finnish) alleles. This alteration has been detected in conjunction with a second MTO1 variant in multiple patients with combined oxidative phosphorylation deficiency (Baruffini, 2013; Kamps, 2018; O'Byrne, 2018). This amino acid position is highly conserved in available vertebrate species. Functional studies in yeast show this variant has a moderate effect on oxidative growth and respiratory activity (Baruffini, 2013). This alteration is predicted to be deleterious by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at